142 related articles for article (PubMed ID: 38482151)
1. Estimating the proportion of relapse following treatment of Visceral Leishmaniasis: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic review.
Chhajed R; Dahal P; Singh-Phulgenda S; Brack M; Naylor C; Sundar S; Alves F; Stepniewska K; Guerin PJ
Lancet Reg Health Southeast Asia; 2024 Mar; 22():100317. PubMed ID: 38482151
[TBL] [Abstract][Full Text] [Related]
2. Recent developments and future prospects in the treatment of visceral leishmaniasis.
Sundar S; Singh A
Ther Adv Infect Dis; 2016 Jun; 3(3-4):98-109. PubMed ID: 27536354
[TBL] [Abstract][Full Text] [Related]
3. Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.
Singh-Phulgenda S; Dahal P; Ngu R; Maguire BJ; Hawryszkiewycz A; Rashan S; Brack M; Halleux CM; Alves F; Stepniewska K; Olliaro PL; Guerin PJ
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009302. PubMed ID: 33780461
[TBL] [Abstract][Full Text] [Related]
4. Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: A systematic review and meta-analysis.
Dahal P; Singh-Phulgenda S; Olliaro PL; Guerin PJ
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009204. PubMed ID: 33725005
[TBL] [Abstract][Full Text] [Related]
5. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
6. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
[TBL] [Abstract][Full Text] [Related]
7. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
Gebreyohannes EA; Bhagvathula AS; Abegaz TM; Seid MA
Infect Dis Poverty; 2018 Oct; 7(1):108. PubMed ID: 30340519
[TBL] [Abstract][Full Text] [Related]
9. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
10. Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis.
Kumar R; Dahal P; Singh-Phulgenda S; Siddiqui NA; Munir A; Naylor C; Wilson J; Buck G; Rahi M; Malaviya P; Alves F; Sundar S; Ritmeijer K; Stepniewska K; Guérin PJ; Pandey K
BMJ Open; 2023 Oct; 13(10):e074679. PubMed ID: 37898487
[TBL] [Abstract][Full Text] [Related]
11. Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
Goyal V; Burza S; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Das VNR; Bern C; Hightower A; Rijal S; Sunyoto T; Alves F; Lima N; Das P; Alvar J
PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007726. PubMed ID: 31557162
[TBL] [Abstract][Full Text] [Related]
12. Leishmaniasis: an update of current pharmacotherapy.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
[TBL] [Abstract][Full Text] [Related]
13. An update on pharmacotherapy for leishmaniasis.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2015 Feb; 16(2):237-52. PubMed ID: 25346016
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
Pandey K; Pal B; Siddiqui NA; Lal CS; Ali V; Bimal S; Kumar A; Verma N; Das VNR; Singh SK; Topno RK; Das P
Indian J Dermatol Venereol Leprol; 2021; 87(1):34-41. PubMed ID: 33580944
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies.
Rodrigo C; Weeratunga P; Fernando SD; Rajapakse S
Clin Microbiol Infect; 2018 Jun; 24(6):591-598. PubMed ID: 29138100
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging medications for the treatment of leishmaniasis.
Chakravarty J; Sundar S
Expert Opin Pharmacother; 2019 Jul; 20(10):1251-1265. PubMed ID: 31063412
[TBL] [Abstract][Full Text] [Related]
20. Haematological dynamics following treatment of visceral leishmaniasis: a protocol for systematic review and individual participant data (IPD) meta-analysis.
Munir A; Dahal P; Kumar R; Singh-Phulgenda S; Siddiqui NA; Naylor C; Wilson J; Buck G; Rahi M; Alves F; Malaviya P; Sundar S; Ritmeijer K; Stepniewska K; Pandey K; Guérin PJ; Musa A
BMJ Open; 2023 Dec; 13(12):e074841. PubMed ID: 38101841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
